Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Treprostinil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR known ✓ | P43119 | 12/20 | 1.00 |
| ▸ | PTGER2 | P43116 | 3/20 | 1.00 |
| ▸ | PTGER1 | P34995 | 3/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 2/20 | 1.00 |
| ▸ | PTGFR | P43088 | 6/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.45 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Treprostinil SCHEMBL11914201 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL4349622 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL9418778 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL14732787 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL11953002 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL4349618 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL24243789 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL4349627 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL22282429 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL21530472 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10729778-B2 | Carrier-linked treprostinil prodrugs | ASCENDIS PHARMA A/S (DK) | 2020-08-04 | — | — | US | disclosed |
| EP-3643306-A2 | CARRIER-LINKED PRODRUGS HAVING REVERSIBLE CARBOXYLIC ESTER LINKAGES | Ascendis Pharma A/S (DK) | 2020-04-29 | — | — | EP | disclosed |
| US-20190105400-A1 | Carrier-Linked Treprostinil Prodrugs | ASCENDIS PHARMA A/S (DK) | 2019-04-11 | — | — | US | disclosed |
| US-9872864-B2 | Sustained release composition of prostacyclin | ASCENDIS PHARMA A/S (DK) | 2018-01-23 | — | — | US | disclosed |
| US-9872864-B2 | Sustained release composition of prostacyclin | ASCENDIS PHARMA A/S (DK) | 2018-01-23 | — | — | US | disclosed |
| US-20140303245-A1 | Sustained Release Composition of Prostacyclin | ASCENDIS PHARMA A/S (DE) | 2014-10-09 | — | — | US | disclosed |
| US-20140303245-A1 | Sustained Release Composition of Prostacyclin | ASCENDIS PHARMA A/S (DE) | 2014-10-09 | — | — | US | disclosed |
| US-20140249093-A1 | Carrier-Linked Prodrugs Having Reversible Carboxylic Ester Linkages | ASCENDIS PHARMA A/S (DK) | 2014-09-04 | — | — | US | disclosed |
| US-20140249093-A1 | Carrier-Linked Prodrugs Having Reversible Carboxylic Ester Linkages | ASCENDIS PHARMA A/S (DK) | 2014-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249093-A1 | Carrier-Linked Prodrugs Having Reversible Carboxylic Ester Linkages | CES2, CES1, APEH | PTGIR 1311/4885PTGER2 1297/4885PTGER1 766/4885 |
| US-10729778-B2 | Carrier-linked treprostinil prodrugs | PAH, SLC16A1, SLC34A3 | PTGIR 19/4885PTGER2 112/4885PTGER1 50/4885 |
| US-20140303245-A1 | Sustained Release Composition of Prostacyclin | PTGIR, PTGIS, PTGS1 | PTGIR 1/4885PTGER2 9/4885PTGER1 4/4885 |
| US-20190105400-A1 | Carrier-Linked Treprostinil Prodrugs | PAH, TK1, SLC16A1 | PTGIR 16/4885PTGER2 137/4885PTGER1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.